GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Blood

Volumn 133, Issue 7, 2019, Pages 697-709

  Sterner, Rosalie M ^a,b   Sakemura, Reona ^c   Cox, Michelle J ^c   Yang, Nan ^c   Khadka, Roman H ^b   Forsman, Cynthia L ^c   Hansen, Michael J ^b   Jin, Fang ^b   Ayasoufi, Katayoun ^b   Hefazi, Mehrdad ^c   Schick, Kendall J ^b   Walters, Denise K ^b   Ahmed, Omar ^d   Chappell, Dale ^d   Sahmoud, Tarek ^d   Durrant, Cameron ^d   Nevala, Wendy K ^b   Patnaik, Mrinal M ^c   Pease, Larry R ^b   Hedin, Karen E ^b   Kay, Neil E ^c   Johnson, Aaron J ^b   Kenderian, Saad S ^b,c,e   more..

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d Humanigen Inc   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHEMOKINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENZILUMAB; TISAGENLECLEUCEL T; LYMPHOCYTE ANTIGEN RECEPTOR; NEUTRALIZING ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL PROLIFERATION; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; CYTOKINE RELEASE SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MONOCYTE; MOUSE; NALM-6 CELL LINE; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; IMMUNOLOGY; IMMUNOPATHOLOGY; INFLAMMATION; METABOLISM; SYNDROME; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL PROLIFERATION; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; MACROPHAGES; MICE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHIMERIC ANTIGEN; SYNDROME; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85058641028     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-10-881722     Document Type: Article

References (31)

1. Kenderian SS, Ruella M, Gill S, Kalos M. Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res. 2014;74(22):6383-6389.
2. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724-740.
3. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
4. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and Young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
5. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377(26):2545-2554.
6. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518.
7. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
8. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404-1419.
9. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017; 45(2):e124-e131.
10. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016; 6(6):664-679.
11. Park JH, Romero FA, Taur Y, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018;67(4):533-540.
12. Gofshteyn JS, Shaw PA, Teachey DT, et al. Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol. 2018;84(4): 537-546.
13. Shalabi H, Wolters PL, Martin S, et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. J Immunother. 2018;41(7):350-358. 10.1097/ CJI.0000000000000241
14. Locke FL, Sattva S, Neelapu NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) [abstract]. Blood. 2017;130(suppl 1). Abstract 1547.
15. Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy. 2017;19(7):867-880.
16. Frey NV, Levine BL, Lacey SF, et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells [abstract]. Blood. 2014;124(21). Abstract 2296.
17. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224): 224ra225.
18. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-195.
19. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15(1):47-62.
20. Crotti C, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther. 2017;11:211-223.
21. Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121(25): 5068-5077.
22. Molfino NA, Kuna P, Leff JA, et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open. 2016; 6(1):e007709.
23. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8): 783-784.
24. Johnson HL, Chen Y, Jin F, et al. CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support. J Immunol. 2012;189(4):1937-1945.
25. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GMCSF) and T-cell responses: what we do and don’t know. Cell Res. 2006;16(2):126-133.
26. Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018;8(6):750-763.
27. Ruella M, Kenderian SS, Shestova O, et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 2017;31(1): 246-248.
28. Kenderian SS, Ruella M, Shestova O, et al. Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model [abstract]. Blood. 2016;128(22). Abstract 652.
29. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739-748.
30. Ruella M, Klichinsky M, Kenderian SS, et al. Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. Cancer Discov. 2017;7(10):1154-1167.
31. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.